| 货号 | AF2604-SP |
| 别名 | ADHR; FGF-23; fibroblast growth factor 23; HPDR2; HYPF; phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor | 全称 | Fibroblast Growth Factor 23 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human FGF-23 in direct ELISAs and Western blots. In Western blots, approximately 25% cross-reactivity with recombinant mouse FGF‑23 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize FGF‑23-induced proliferation in the NIH‑3T3 mouse embryonic fibroblast cell line. The Neutralization Dose (ND50) is typically 5-15 µg/mL in the presence of 1 µg/mL Recombinant Human FGF‑23, 5 µg/mL Recombinant Mouse Klotho, and 10 µg/mL heparin. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 8074 (Human); 64654 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. FGF23 is endogenously phosphorylated in bone cells. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human FGF-23 Tyr25-Ile251 Accession # Q9GZV9 |
| 内毒素水平 | <0.24 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Fibroblast growth factor 23 (FGF-23) is a 30-32 kDa member of the FGF family, within a subfamily that also includes FGF-19 and FGF-21. FGF proteins contain a 120 amino acid (aa) core FGF domain that exhibits a beta -trefoil structure (1, 2). FGF-19 subfamily members are highly diffusible molecules owing to their poor ECM/heparin sulfate binding and plasma-stabilizing intramolecular folds (2-4). Mature human FGF-23 contains an atypical (very low affinity) heparin binding site (aa 134‑162), a proteolytic cleavage site (Arg179-Ser180), and multiple O-linked glycosylation sites with Thr178 being of particular importance (4-7). O-linked glycosylation at Thr178 blocks the cleavage of FGF-23, thereby preventing loss of FGF-23 activity (7, 8). Mature human FGF-23 shows 72% aa identity to mouse FGF-23 and is active on mouse cells (6). FGF-23 exerts its effects through a ternary complex that includes Klotho and an FGF receptor (FGF R4 or the "c" isoforms of FGF R1 or FGF R3). Klotho has a restricted distribution that limits FGF-23 activity (9-11). FGF-23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels (12). FGF-23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by downregulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate (13). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by FGF‑23 and Neutralization by Human FGF‑23 Antibody. In the presence of Recombinant Mouse Klotho (5 µg/mL, Catalog # 1819-KL) and heparin (10 µg/mL), Recombinant Human FGF‑23 (Catalog # 2604-FG) stimulates proliferation in the NIH‑3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, proliferation elicited by Recombinant Human FGF‑23 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human FGF‑23 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2604). The ND50 is typically 5‑15 µg/mL. |
